2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6354 Association of GLP-1 receptor agonist exposure with survival and clinical outcomes in patients with chronic myeloid leukemia

Omar Farooq Amir, MD, Dominic Earl Mitchell Jarrett, MD2, Travis Edward Stueber, DO3, Anum Jalil4, Ahmed Bashir Sukhera, MD5, Prashanth Kotla, MD6, Yajur Arya, MD7, Arshi Syal, MD8, Colton Jones, MD, Hematology, Oncologyfellow9, Anand Karnad, MD10
1 University of Texas Health Science Center, San Antonio, Texas, United States
2 University of Miami/Jackson Health System Internal Medicine Residency, Miami, Florida, United States
3 University of Texas Health Science Center, San Antonio, Texas, United States
4 University of Texas Health Science Center, San Antonio, Texas, United States
5 Texas Tech University Health Sciences Center, Odessa, Texas, United States
6 University of Texas Health Science Center, San Antonio, Texas, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 Mayo Clinic, Jacksonville, Florida, United States
9 University of Texas Health Science Center, San Antonio, Texas, United States
10 UT Health San Antonio Mays Cancer Center, San Antonio, Texas, United States

Background
Chronic myeloid leukemia (CML) outcomes have markedly improved with tyrosine kinase inhibitors (TKIs). Despite these advances, relapses, treatment failure, and treatment-related toxicity remain ongoing challenges. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may influence disease outcomes beyond glycemic control by modulating metabolic pathways, inflammation, and the tumor microenvironment. Accumulating observational studies suggest GLP-1RAs may influence outcomes in hematologic malignancies through metabolic and immune-mediated pathways, yet their role in CML remains unexplored. To our knowledge, this is the first retrospective study to investigate the association of GLP-1RA exposure with survival, relapses, and treatment-related tolerability among patients with CML.

Methods
This retrospective cohort study utilized the TriNetX global federated research network, a large- scale platform aggregating de-identified electronic health record data from participating healthcare organizations. The study population included adults (≥18 years) with a confirmed CML diagnosis (ICD-10) between January 2000 and January 2025. Patients were classified into a GLP-1RA-exposed cohort and a non-exposed comparator cohort based on documented medication history. Inclusion in the GLP-1RA cohort required treatment initiation following both CML diagnosis and a qualifying diagnosis of obesity or type 2 diabetes (T2DM). To reduce selection bias, 1:1 propensity score matching was conducted on baseline covariates including demographics, comorbid conditions, BMI, HbA1c, and TKI exposure. Overall survival (OS) served as the primary outcome. Secondary outcomes encompassed remission rates (ascertained via ICD-10 remission codes), relapse, and selected treatment-related adverse events including pancytopenia, edema, diarrhea, skin rash, fatigue, and myalgia. Hazard ratios with 95% confidence intervals were derived using Cox regression modeling. Immortal time bias was addressed through a 3-month landmark design.

Results
After propensity score matching, 3,666 patients were included (n=1,833 per cohort). Median age was 57 vs. 58 years, 72% vs. 74% White, and 44% male in both cohorts. Median BMI was 35 vs. 29 kg/m2; median HbA1c was 6.5% vs. 5.8%. BMI and HbA1c were included as covariates in the Cox model. At median follow-up of 1,020 days, GLP-1RA exposure was associated with significantly improved OS (HR 0.17; 95% CI, 0.13-0.22; p<0.001; 66 vs. 310 deaths). GLP-1RA exposure was associated with higher remission rates (HR 1.40; 95% CI, 1.15-1.69; p<0.001). Relapse rates were not significantly different between cohorts (HR 0.84; 95% CI, 0.53-1.33; p=0.452). Exploratory analyses of adverse events showed a lower risk of pancytopenia (HR 0.75; 95% CI, 0.57-0.99, p=0.039). No significant differences were observed in edema (HR 1.20; 95% CI, 1.00–1.45; p=0.053), diarrhea (HR 1.11; 95% CI, 0.91–1.35; p=0.311), skin rash (HR 1.18; 95% CI, 0.95–1.47; p=0.134), fatigue (HR 0.91; 95% CI, 0.74–1.10; p=0.327), or myalgia (HR 1.21; 95% CI, 0.92–1.59; p=0.165).

Conclusions
In this real-world propensity-matched cohort of patients with CML, GLP-1RA exposure was associated with an 83% reduction in the hazard of death and higher remission rates without an observed increase in relapse. The findings highlight the potential of GLP-1RA therapy as an adjunctive strategy in CML. Key limitations include residual confounding, healthy user bias, limited availability of molecular response data, CML phase data, and TKI treatment data. Prospective trials are warranted to validate these associations.

Omar Farooq Amir, MD: No relevant conflicts of interest to declare.